TOG Review (RCOG Journal)

MRCOG Part 2

Maternal Medicine

Management of gynaecological cancer in pregnancy

Key Statistics

  • 1 in 1000 — Malignancy in pregnancy (all types)
  • 1–10/10,000 — Cervical cancer in pregnancy
  • 2–10/100,000 — Malignant adnexal mass in pregnancy

Don't-miss facts

  1. Do not perform a cervical smear in pregnancy; refer suspicious lesions for colposcopy and directed biopsy

  2. MRI yes, CT no for staging in pregnancy; radioisotope therapy is contraindicated (crosses placenta)

  3. Cone/LLETZ bleeding risk 4–15%; do it early. Lymphadenectomy very difficult >15 weeks

  4. Adnexal surgery window 12–27 weeks; laparoscopy only if low risk and <20–22 weeks; open if high risk (avoid spillage/upstaging)

  5. CA125 >65 IU/ml in 16% of pregnancies – do not use routinely; AFP physiologically raised but much higher with germ cell tumours

  6. No chemotherapy in the first trimester; bevacizumab contraindicated; no breastfeeding on platinum/taxane (excreted >2 weeks)

  7. Pelvic radiotherapy is not compatible with fetal life – if unavoidable, 3rd trimester, deliver by caesarean first and transpose ovaries out of the field

  8. Vulval surgery: defer to postpartum if ≥36 weeks; previous periurethral/perivaginal excision is a relative contraindication to vaginal delivery

Delivery flags

Prior trachelectomy → caesarean mandatory Prior pelvic RT → IUGR, deliver ~34 weeks

Borderline ovarian tumour → continue pregnancy, aim vaginal delivery

Abbreviation Key

  • LLETZ — large loop excision of the transformation zone
  • CA125 — cancer antigen 125
  • MDT — multidisciplinary team
  • AFP — alphafetoprotein
  • FIGO — International Federation of Gynecology and Obstetrics
  • BSO — bilateral salpingo-oophorectomy
  • MRI — magnetic resonance imaging
  • GROINSS — GROningen INternational Study on Sentinel Nodes in Vulvar Cancer
  • CT — computed tomography
  • VEGF-A — vascular endothelial growth factor A
  • NICE — National Institute for Health and Care Excellence
  • TOP — termination of pregnancy
  • RMI — risk of malignancy index
  • IUGR — intrauterine growth restriction

Source: China S, Sinha Y, Sinha D, Hillaby K. Management of gynaecological cancer in pregnancy. The Obstetrician & Gynaecologist 2017;19:139–146. doi:10.1111/tog.12367

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free